ABG Sundal Collier acted as joint bookrunner in connection with the SEK 244 directed share issue in Wilson Therapeutics

Wilson Therapeutics AB today announces that the company has successfully completed a directed share issue of approximately SEK 244m. The board of directors of Wilson Therapeutics has, based on the issue authorization granted by the annual general meeting 2017, resolved on a directed share issue of 2,572,024 new shares at a subscription price of SEK 95 per share (the “Issue”), which means that the Company will receive gross proceeds of approximately SEK 244 million. The subscription price in the Issue has been determined through an accelerated bookbuilding procedure. Strong demand was generated from reputable institutions and sector specialist funds, internationally and in Sweden, such as Oppenheimer, Polar Capital, Sphera Funds Management, Granite Point Capital Management and Handelsbanken.
 

About Wilson Therapeutics

Wilson Therapeutics is a biopharmaceutical company, based in Stockholm, Sweden, that develops novel therapies for patients with rare copper-mediated disorders. Wilson Therapeutics’ lead product, WTX101, is in development as a novel treatment for Wilson Disease. A Phase 2 clinical study has been successfully completed and preparations for a pivotal Phase 3 study are ongoing. Wilson Therapeutics is listed in the Mid Cap segment on Nasdaq Stockholm with the stock ticker WTX